ORTX Orchard Therapeutics plc

14.46
0  0%
Previous Close 14.46
Open
Price To Book 4.33
Market Cap 1,245,998,404
Shares 86,168,631
Volume 0
Short Ratio
Av. Daily Volume 212,412

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 data to be presented February 24, 2019.
OTL-102
X-linked chronic granulomatous disease (X-CGD)
Phase 1/2 engraftment data due 2019.
OTL-101
Adenosine deaminase severe combined immunodeficiency (ADA-SCID)
Phase 1/2 data presented April 29, 2019.
OTL-300
Transfusion-dependent beta-thalassemia (TDBT)
Phase 2 engraftment data due 2019.
OTL-200
Metachromatic leukodystrophy (MLD)
Phase 1/2 initiation of dosing announced April 25, 2019. Three-year follow up data due 2019.
OTL-103
Wiskott-Aldrich Syndrome (WAS)

Latest News

  1. Orchard Therapeutics to Present at the Goldman Sachs 40th Annual Global Healthcare Conference on June 12, 2019
  2. The Daily Biotech Pulse: Takeda Pulls Plug On Amyloidosis Drug Trial, Chiasma Preps For Drug Launch With New CEO Appointment, Orchard Prices Offering
  3. Orchard Therapeutics Announced Pricing of Public Offering
  4. Orchard Therapeutics Launches Proposed Public Offering
  5. Health Care Digest: Why California biotech thrives, small company looks to crash NASH bash, meeting up at BIO
  6. Orchard Therapeutics plc (ORTX) Q1 2019 Earnings Call Transcript
  7. Orchard Therapeutics Announces Expansion of Neurometabolic Disease Portfolio and Reports First Quarter 2019 Financial Results
  8. Orchard Therapeutics, Fondazione Telethon and Ospedale San Raffaele Announce Exclusive Worldwide License Agreement for the Treatment of MPS-I
  9. Orchard Therapeutics to Webcast Conference Call of First Quarter 2019 Financial Results on May 28, 2019
  10. Orchard Therapeutics Announces Clinical Proof-of-Concept Data for Gene Therapy OTL-300 Demonstrating Efficacy in Transfusion-Dependent Beta-Thalassemia
  11. Orchard Therapeutics Strengthens Commercial Leadership Team with Appointment of Francis Pang as Vice President of Global Market Access
  12. Orchard Therapeutics Announces First Patient Dosed with Cryopreserved Formulation of OTL-103 Gene Therapy for the Treatment of Wiskott-Aldrich Syndrome
  13. Orchard Therapeutics Announces Presentation of Clinical Proof-of-Concept for OTL-300 for the Treatment of Transfusion-Dependent Beta-Thalassemia at the 22nd American Society of Gene & Cell Therapy Annual Meeting
  14. Will Orchard Therapeutics Continue to Surge Higher?
  15. Orchard Therapeutics Presents New Registrational Data Demonstrating Sustained Clinical Benefit of OTL-200 for the Treatment of MLD
  16. Orchard Therapeutics Reports 2018 Financial Results and Reviews Recent Business Highlights
  17. Orchard Therapeutics Strengthens Global Manufacturing and Supply Chain Leadership with Appointment of Ran Zheng as Chief Technical Officer
  18. What Kind Of Shareholders Own Orchard Therapeutics plc (NASDAQ:ORTX)?
  19. Orchard Therapeutics to Webcast Conference Call of 2018 Financial Results on March 21, 2019
  20. Orchard Therapeutics Announces Acceptance of OTL-200 Abstract for MLD at the 45th Annual Meeting of the European Society for Blood and Bone Marrow Transplantation (EBMT)